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Purpose: Stargardt disease is the most common inherited juvenile macular dystrophy
and is characterized by yellowish ﬂecks across the posterior pole. The purpose of this study
was to investigate ﬂuorescence lifetime changes of retinal ﬂecks over time using
ﬂuorescence lifetime imaging ophthalmoscopy.
Methods: Longitudinal ﬂuorescence lifetime data of 12 patients with Stargardt disease
(mean age ± SEM, 42.25 ± 2.1 years; range, 28–58 years) were acquired using a ﬂuores-
cence lifetime imaging ophthalmoscope based on a Heidelberg Engineering Spectralis
system. Retinal autoﬂuorescence was excited with a 470-nm laser. The emitted ﬂuores-
cence was detected in two wavelength channels: a short spectral channel (498–560 nm)
and a long spectral channel (560–720 nm). The mean retinal autoﬂuorescence lifetimes
were calculated and further analyzed with corresponding color fundus images, autoﬂuor-
escence intensity images, and spectral domain optical coherence tomography. Patients
were classiﬁed into three subtypes.
Results: All patients with Stargardt disease displayed characteristic autoﬂuorescence
lifetime patterns. Mean ﬂuorescence lifetime values within areas of yellow ﬂecks were
signiﬁcantly prolonged (long spectral channel 484 ps) compared with the surrounding
tissue (long spectral channel 297 ps). In 91.6% of the eyes, ﬂecks with short ﬂuorescence
lifetimes (long spectral channel 255 ps) were identiﬁed. Short lifetime ﬂecks progressed to
ﬂecks with characteristic long lifetimes in 75.1% of eyes within a mean interval of 29.2
months (range 3–45 months). Between baseline and follow-up, the rate of newly developed
short lifetime ﬂecks (number/per year) based on subtypes was 2.62 in Group 1, 1.43 in
Group 2, and 0.81 in Group 3.
Conclusion: Recent onset ﬂecks in Stargardt disease display short ﬂuorescence
lifetimes and convert into longer ﬂuorescence lifetime ﬂecks over time. This transition
may represent a change in the composition of retinal deposits with accumulation of
lipofuscin and retinoid by-products from the visual cycle. With emerging treatment options,
these ﬁndings may prove useful to monitor disease progression and therapeutic effects.
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Stargardt disease (STGD) is the most common in-herited macular dystrophy. It is a form of macular
degeneration initially described by Stargardt in 1909.1
Stargardt disease classically presents during the ﬁrst
two decades of life and is characterized by a progres-
sive bilateral loss of central vision. Morphological fea-
tures include central macular atrophy and well-deﬁned
yellowish deposits visible on the posterior pole around
the macular, known as “ﬂecks.”1,2 Histologically,
ﬂecks are located at the level of the retinal pigment
epithelium (RPE).3,4
Over the course of the disease, initially well-deﬁned
ﬂecks progress outward from the central macula in
a centrifugal pattern. Flecks then fade, leaving poorly
demarcated yellow lesions and residual atrophy.2,5,6
Thus, at advanced stages of the disease, a progressive
bilateral atrophy of the RPE, photoreceptors, and cho-
roidal vasculature can be found.7 The severity of fun-
dus abnormalities seen on ophthalmoscopy is often not
directly associated with the visual acuity. However,
the overall prognosis of STGD is poor, and visual









































Stargardt disease is predominately inherited in an
autosomal recessive trait, and most cases are caused
by pathogenic variants in the retinal-speciﬁc ATP-
binding cassette transporter gene ABCA4, located on
chromosome 1p13 (STGD1; OMIM #248200).10–12
ABCA4 expression is predominantly localized to the
rim of photoreceptor outer segments and at lower
levels in the retinal pigment epithelium.13 The AB-
CA4 transporter ﬂips the N-retinylidene-phosphati-
dylethanolamine (N-ret-PE) that forms in the visual
cycle by reversible combination of toxic retinalde-
hyde with phosphatidylethanolamine (PE), from the
luminal to cytoplasmic surface of photoreceptor
outer disc membranes. In the absence of ABCA4
ﬂippase activity, clearance of retinaldehyde is de-
layed, favoring a secondary condensation of N-ret-
PE with another retinaldehyde to form phospholipid-
conjugated bisretinoids, v.g. dihydro-N-
retinylidene-N-retinyl-phosphatidylethanolamine
(A2PE-H2), or its oxidized form (A2PE).12,14 Char-
acteristic phenotypic features, such as pisciform
ﬂecks and atrophy, are then believed to develop as
a result of the accumulation of these retinoid by-
products or lipofuscins in the RPE.10 In rare cases,
STGD is caused by dominantly inherited variants in
ELOVL4 encoding the elongation of very long chain
fatty acids protein 4 (STGD3; OMIM #600110) and
in PROM1 encoding the rim protein prominin-1
(STGD4; OMIM #603786).
Several noninvasive imaging techniques have been
established in the diagnosis of STGD, and for
monitoring disease progression. Spectral domain opti-
cal coherence tomography (OCT) is a recognized
imaging tool that provides morphologic information
by visualizing the retinal architecture. Spectral domain
OCT may demonstrate thinning of retinal layers and
a loss of photoreceptor segment layers.15,16
Fundus autoﬂuorescence (FAF) intensity imaging is
an established imaging technique providing informa-
tion on the retinal status by enabling the visualization
of hyperautoﬂuorescent material such as bisretinoid
components, such as lipofuscin, originating from the
RPE.17 In early stage of STGD, FAF imaging reveals
hyperautoﬂuorescent lesions consistent with visible
ﬂecks on fundus examination. In later stages, hypoau-
toﬂuorescent areas appear, consistent with RPE atro-
phy and photoreceptor loss.6
Despite substantial research efforts in the past
decades, there are no approved therapeutic treat-
ments for STGD. The disease causes signiﬁcant
morbidity with psychological and economic impli-
cations. However, promising new options, including
gene replacement therapy, stem cell transplantation,
and deuterated vitamin A, are emerging and are
currently being reviewed in clinical trials.18,19 A fur-
ther challenge researchers face in treating STGD is
the lack of a highly sensitive measurement tool to
monitor short-term changes in disease progression.19
This will be vital to assess effects of future therapies
accurately.
Fluorescence lifetime imaging ophthalmoscopy
(FLIO) measures lifetimes of endogenous retinal
ﬂuorophores after excitation using a picosecond-
pulsed blue laser light. A previous report from our
group demonstrated characteristic ﬂuorescence life-
time changes across the posterior pole in patients
with STGD. In this previous study, retinal ﬂecks
with a broad range of autoﬂuorescence lifetimes
were identiﬁed, and it was speculated that short
lifetime ﬂecks represent recent lesions, whereas
ﬂecks with longer lifetimes represent older lesions.20
The aim of this study was to investigate the dynam-
ics of ﬂuorescence lifetimes within retinal ﬂecks
over time.
Methods
Twelve patients with a clinical diagnosis of STGD
were included in the study. The patients were consec-
utively recruited at the University Hospital in Bern,
Switzerland. The diagnosis of STGD was established
by ﬁndings on clinical examination and ancillary
studies including color fundus images, FAF intensity
images, and electroretinographic results.21 Moreover,
11 of 12 patients with STGD included had a molecular
diagnosis of STGD (see Table 1, Supplemental
Digital Content 1, http://links.lww.com/IAE/A990).
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All patients had a baseline and a follow-up exam-
ination. At each visit, best-corrected visual acuity
(BCVA; according to Early Treatment Diabetic Ret-
inopathy Study [ETDRS] letters22) was measured in
all patients, and a general dilated ophthalmologic
examination was performed. Maximal pupil dilation
was achieved using tropicamide 0.5% and phenyleph-
rine HCl 2.5%. Fundus color images (Zeiss FF
450plus; Zeiss, Oberkochen, Germany), OCT scans
of the macula (Heidelberg Spectralis HRA + OCT;
Heidelberg Engineering, Heidelberg, Germany), and
ﬂuorescence lifetime images were obtained of both
eyes.
Patients with STGD were assigned to phenotypic
subtypes at baseline and follow-up. Based on the
clinical appearance of the color fundus and FAF
images, patients were assigned to one of three groups:
1. Group I: ﬂecks and atrophy are conﬁned to the
central macular area.
2. Group II: ﬂecks are scattered, can spread nasally to
the optic disk, and/or exceed the vascular arcades.
3. Group III: ﬂecks are ill-deﬁned “resorbed” lesions,
and extensive RPE atrophy is visible.23
The study was conducted at the Department of
Ophthalmology at the University Hospital in Bern,
Switzerland, with the approval of the local ethics
committee and in accordance with the Declaration of
Helsinki. All participants provided written informed
consent before study entry. This study is registered at
ClinicalTrials.gov as “Measurement of Retinal Auto-
ﬂuorescence with a Fluorescence Lifetime Imaging
Ophthalmoscope (FLIO Group),” with the identiﬁer
number NCT01981148.
Fluorescence Lifetime Imaging Ophthalmoscope
Fluorescence lifetime imaging ophthalmoscope,
based on an HRA Spectralis system (Heidelberg
Engineering), was used to obtain retinal ﬂuorescence
lifetime data. The principles and details of FLIO have
been described elsewhere.22,24
In summary, the technique is based on the excitation
of retinal autoﬂuorescence using a 470-nm pulsed laser
at 80-MHz repetition rate. Highly sensitive hybrid
photon-counting detectors (HPM-100–40; Becker &
Hickl, Berlin, Germany) were used for the registration
of emitted ﬂuorescence light by time-correlated single-
photon counting modules (SPC-150; Becker & Hickl).
Emitted ﬂuorescence photons were measured in two
separate wavelength spectrums: a short spectral chan-
nel (SSC: 498–560 nm) and a long spectral channel
(LSC: 560–720 nm). In both wavelength channels, at
least 1,000 photons per pixel were obtained, which
requires scan duration of 90 seconds per eye approx-
imately in patients with STGD. During data accumu-
lation, an eye movement tracking system with a high-
contrast confocal infrared image ensures the correct
location of each detected photon within a ﬁeld of
256 · 256 pixels.
Fluorescence Lifetime Data Analysis
Fluorescence lifetime data collection resulted in
a decay curve which was biexponentially approxi-
mated using SPCImage software version 4.6 (Becker
& Hickl). The chi-square value evaluated appropriate-
ness of the exponential ﬁt. The resulting short and long
lifetime components (T1 and T2) along with their
respective relative amplitudes a1 and a2 were used
to calculate the mean ﬂuorescence lifetime Tm, which
signiﬁes the amplitude weighted mean ﬂuorescence
lifetime.
The mean ﬂuorescence lifetimes were analyzed
using “FLIO reader” software (ARTORG Center for
Biomedical Engineering Research, University of Bern,
Switzerland). To spatially quantify retinal autoﬂuores-
cence lifetimes, a standard ETDRS grid was used with
following circle diameters: 1 mm for the central area,
3 mm for the inner ring, and 6 mm for the outer ring.
Smaller region of interests with diameters of 0.16 mm
and 0.5 mm were used to analyze speciﬁc areas of
interest, for example, ﬂecks. Fluorescence lifetimes
within ﬂecks were analyzed by averaging three regions
of interest.
Statistical Data Analysis
Fluorescence lifetime values for the SSC and the
LSC were analyzed separately. All data were presented
as mean ± SEM. Statistical analysis was performed
using GraphPad (Prism 6; GraphPad Software, Inc,
La Jolla, CA). To compare the results, the Mann–
Whitney test with a conﬁdence interval of 95% was
used. P values ,0.05 were considered as statistically
signiﬁcant. A stepwise forward regression analysis
was performed using SigmaPlot Version 12.3 (Systat
Software, Inc, San Jose, CA).
Results
Twenty-four eyes of 12 patients with a clinical
diagnosis of STGD were included in this study (53.8%
female). Patient characteristics are shown in Table 1.
The mean age ± SEM at baseline was 42.25 ± 2.1
years (range, 26–56). All participants were white,
phakic with clear media, and had no concomitant oph-
thalmic diseases. The examined patients displayed
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various stages of hyperautoﬂuorescent ﬂecks and hy-
poautoﬂuorescent lesions, consistent with RPE
changes and atrophy. All patients had a baseline and
at least one follow-up examination with a mean inter-
val of 29.2 months (range, 3–45 months). All patients
developed new ﬂecks during the clinical follow-up
period.
Mean age at the initial diagnosis of STGD was 29.7
± 3.1 years (range 12–43). The mean disease duration
at the time of the ﬁrst and the last FLIO measurement
was 12.1 ± 3.1 years (range, 0.08–31), and 14.6 ± 3.24
years (range, 5–30), respectively. The mean BCVA at
baseline and at follow-up was 53.6 ± 4.9 (range
17–84) and 51.2 ± 4.8 (range 16–83) ETDRS letters,
respectively, with a mean EDTRS visual acuity reduc-
tion during the follow-up interval of 2.4 letters. There
was a signiﬁcant correlation between the BCVA and
the mean ﬂuorescence lifetime of the central ETDRS
subﬁeld in both spectral channels when analyzing the
data of all study eyes at baseline (SSC: r2 = 0.35, P =
0.002; LSC: r2 = 0.32, P = 0.004) and follow-up (SSC:
r2 = 0.51, P , 0.0001; LSC: r2 = 0.45, P = 0.0001)
(Figure 1). A central atrophic lesion was found in
33.3% patients (10 eyes), with a mean size of
7.35 mm2 (range 0.48–20.3 mm2) at baseline, and
10.6 mm2 (range 1.69–28.7 mm2) at follow-up. The
mean progression rate of the atrophic area was
1.7 mm2 per year.
Autoﬂuorescence Lifetimes in Patients With
Stargardt Disease
The white-yellow STGD ﬂecks visible on fundus
examination correlated with hyperautoﬂuorescent le-
sions in FAF intensity images and hyperreﬂective
changes seen in OCT. In FLIO, ﬂecks exhibited both
short and long ﬂuorescence lifetimes, when compared
with the surrounding retina, and were represented as
red and blue lesions in color-coded images with
a range between 200 ps (red) and 600 ps (blue).
Most ﬂecks displayed long (blue) ﬂuorescence
lifetimes (SSC: 4,715 ± 17 ps; LSC: 484 ± 21 ps).
However, in 91.7% (n = 22) of eyes, a smaller number
of ﬂecks with shorter lifetimes, color-coded in red
(SSC: 265 ± 2 ps; LSC: 255 ± 4 ps), were identiﬁed
(Figure 2).
Compared with the surrounding retina (SSC: 270 ±
6 ps; LSC: 297 ± 7 ps), Ƭm was signiﬁcantly pro-
longed in long ﬂuorescence lifetime ﬂecks by +74%
in the SSC and +63% in the LCS (both P , 0.0001).
While in short ﬂuorescence lifetime ﬂecks, Ƭm was
shortened by 22% in the SSC and 216% in the
LSC (SSC: P = 0.21, LSC: P , 0.0001) compared
with the surrounding retina.
Fluorescence lifetime imaging ophthalmoscopy was
used to examine the progression of the disease in our
study eyes. Long ﬂuorescence lifetime ﬂecks pre-
sented as isolated deposits or as several ﬂecks merging
with each other in a meshwork pattern. As expected,
ﬂeck formation progressed centrifugal outward from
the central macular area as the disease advanced. On
follow-up, new ﬂecks developed in all patients;
however, the rate and extent varied between patients.
Short ﬂuorescence lifetime ﬂecks. A larger number
of short ﬂuorescence lifetime ﬂecks were identiﬁed in
patients at early stages of disease (Group 1 and Group
2), while at later stages, they were only found
occasionally. The ratio of short ﬂuorescence lifetime
ﬂecks identiﬁed at baseline between Group 1 versus
Group 3 was 9:5. Quantitative analysis of ﬂecks with
short ﬂuorescence lifetimes at two points in time
Table 1. Baseline Patient Characteristics
Patient ID Sex Baseline Age, year Age of Onset, y
Visual Acuity Phenotype Atrophy
Right Left Right Left Right Left
STGD 1 M 34 28 80 81 2 2 — —
STGD 2 M 33 30 79 84 2 2 — —
STGD 3 M 53 40 35 34 2 2 Y Y
STGD 4 F 43 12 32 34 3 3 GA GA
STGD 5 M 41 34 38 40 2 2 Y Y
STGD 6 M 45 18 19 17 3 3 GA GA
STGD 7 F 45 40 82 83 2 3 — —
STGD 8 F 56 33 34 36 2 2 GA GA
STGD 9 M 47 42 70 84 1 2 — —
STGD 10 M 41 18 44 47 2 2 GA GA
STGD 11 F 26 18 34 34 2 2 GA GA
STGD 12 F 43 43 83 83 2 2 — —
Patient ID number, sex, age, age of onset, BCVA (ETDRS letters) at the last follow-up, fundus phenotype 1 to 3 according to Fishman
classiﬁcation, presence of areas with geographic atrophy (GA), and presence of atrophy (Y).
M, male; F, female.
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(baseline and last follow-up) revealed that new ﬂecks
visible in FLIO developed at a rate of 2.62/year in
Group 1, 1.43/year in Group 2, and 0.81/year in Group
3. Short lifetime lesion progressed to ﬂecks with
characteristic long lifetimes in 75.1% (n = 22) within
29.2 months. In the transition phase, longer lifetimes
initiate in the center of the ﬂecks, and radiate outward
with time. Borders of short lifetime ﬂecks shifted to
long lifetimes last (Figure 3).
Long ﬂuorescence lifetime ﬂecks. In general, there
was a predominance of long ﬂuorescence lifetime
ﬂecks in all stages of STGD in our cohort. On
analysis of long lifetime ﬂecks, borders were identi-
ﬁed to feature shorter mean ﬂuorescence lifetime
values than the center of the ﬂeck (SSC: 446.5 ± 17
ps, vs. 522.6 ± 20, P , 0.0001) (LSC: 462.7 ± 14 ps,
vs. 548.3 ± 21 ps, P , 0.0001). Borders demon-
strated progression from sharp deﬁned edges to
a more diffuse pattern (Figure 4).
Correlation of Fluorescence Lifetime Data With
Optical Coherence Tomography Findings
Colocalization of ﬂecks in FLIO with OCT dis-
played hyperreﬂective material of variable size and
shape. At the level of the ﬂecks, OCT bands displayed
convex, pyramidal-shaped, or ill-deﬁned deposits,
interrupting the photoreceptor ellipsoid zone (EZ)
and/or external limiting membrane bands. Some
deposits displayed hyperreﬂective foci extending into
the outer nuclear layer, with a remaining connection to
the RPE. Depending on the location of hyperreﬂective
deposits in OCT, FLIO images displayed characteristic
lifetime patterns. Long ﬂuorescence lifetime ﬂecks
generally demonstrated intraretinal migration of de-
posits of varying extents (Figures 4 and 5), while short
ﬂuorescence lifetime ﬂecks usually presented as dome-
shaped deposits located within the outer retina at the
level of the RPE, with displacement or interruption of
the photoreceptor segments (Figure 3).
Individual Fluorescence Lifetime Components
As described in the method section, Tm is composed
of the separate lifetimes components T1 (short portion)
and T2 (long portion), along with their corresponding
amplitudes or intensities (a1 and a2). We analyzed
these individual ﬂuorescence lifetime components
independently using 2D histograms to observe their
effect on Tm as described in previous publications.22,24
Our data revealed that both short and long ﬂuores-
cence lifetime ﬂecks can be isolated from the surround-
ing retina. Short lifetime ﬂecks characteristically
showed a shorter T1 and T2 component in comparison
to the surrounding retina and the long lifetime ﬂecks
(Figure 5).
Regression Analysis
The inﬂuence of the independent variables patient’s
age, disease duration, and Fishman score was analyzed
against the dependent variables mean ﬂuorescence
lifetime (Tm) in the SSC and the LSC. When analyz-
ing mean ﬂuorescence lifetime values within the cen-
tral ETDRS grid area, the disease duration
signiﬁcantly contributed to the ability of the equation
to predict lifetimes in the short and long wavelength
spectrum (SSC: P = 0.02 and LSC: P = 0.04). When
analyzing unaffected surrounding retina, only age
Fig. 1. Correlation of BCVA (ETDRS letters) with mean ﬂuorescence
lifetime (ps) within the central ETDRS subﬁeld of the short (white
circle, SSC, 498–560 nm) and the long (black circle, LSC) spectral
channels at (A) baseline (SSC: r2 = 0.35, P = 0.002; LSC: r2 = 0.32, P =
0.004) and (B) follow-up (SSC: r2 = 0.51, P , 0.0001; LSC: r2 = 0.45,
P = 0.0001). Representative ﬂuorescence lifetime (FLIO, LSC) images
of three identiﬁed groups and correlating OCT scan of the indicated
lines in the FLIO images are shown below.
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signiﬁcantly correlated with longer mean ﬂuorescence
lifetimes within the SSC (P = 0.006).
Discussion
In this prospective study, we investigated retinal
ﬂuorescence lifetimes in 24 eyes of patients with
STGD using fundus autoﬂuorescence lifetime
(FLIO) imaging. Previously described characteristic
lifetime patterns20 were conﬁrmed. Our data showed
that most retinal hyperautoﬂuorescent ﬂecks and de-
posits displayed longer lifetimes compared with the
surrounding retina. However, particularly at early
stages of disease (Groups 1 and 2), lesions with very
short ﬂuorescence lifetimes were identiﬁed. These
lesions were more apparent in the LSC (560–720
nm). On correlation to other imaging modalities,
we observed that ﬂecks with short ﬂuorescence life-
times were either not yet visible, or faint and
ill-deﬁned on FAF intensity images, while ﬂecks
with prolonged lifetimes were clearly identiﬁable.
Interestingly, our follow-up measurements showed
that lesions with initially short lifetime values which
were faintly visible in FAF intensity measurements
progressed to ﬂecks which were clearly visible as
hyperautoﬂuorescent ﬂecks and displayed long ﬂuo-
rescence lifetimes. These results are in keeping with
our previous study of FLIO in STGD.20 In this
study, we provide evidence that ﬂecks with short
lifetimes occur more frequently at earlier and more
active stages of the disease, and may be the result
from the buildup of intermediate components of the
retinoid cycle.11 On the other hand, blue ﬂecks rep-
resent a more advanced stage of the lesion, possibly
indicating a more severe dysfunction of the under-
lying retina as by-products of the visual cycle accu-
mulate. Sparrow et al25 proposed that in STGD by-
products of the visual cycle can buildup in the outer
segment of photoreceptor cells.
Fig. 2. A. Quantitative analysis
of mean retinal autoﬂuorescence
lifetime values in the SSC and
LSC in patients with STGD.
Following areas were analyzed:
surrounding retinal tissue ( ),
ﬂecks with long ( ) and short
( ) ﬂuorescence lifetimes. B. A
small region of interest (circle
diameter: 0.16 mm) was used to
investigate mean retinal auto-
ﬂuorescence lifetimes within
short lifetime ﬂecks, long life-
time ﬂecks, and the surrounding
retina. Areas of interest repre-
sent a mean value of three
individual measurement loca-
tions. Fluorescence lifetime data
of both spectral channels were
analyzed separately.
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Histopathological studies suggest that the hyper-
autoﬂuorescent ﬂecks originate from lipofuscin accu-
mulation in the RPE cells, which in STGD occurs at an
accelerated rate in comparison with the normal aging
process.26,27 Buildup of ﬂuorescent lipofuscin in the
RPE is a hallmark of STGD, and the possible disease
mechanism due to the dysfunction of the ABCA4 ﬂip-
pase could be the following.13 After photoactivation of
rhodopsin, all-trans retinal builds up in the photorecep-
tor outer segments and readily forms N-retinylidene-
phosphatidylethanolamine (N-ret-PE) by binding to
amine groups of phosphatidylethanolamine (PE). Loss
of ABCA4 ﬂippase activity reduces clearance of all-
trans retinal and favors its condensation with a second
retinaldehyde to form the bisretinoids A2PE. On phago-
cytosis, A2PE is converted into the major lipofuscin
ﬂuorophore A2E (N-retinylidene-N-retinylethanolamine)
in the acidic environment of RPE phagosomes.26–28
The recent identiﬁcation of ABCA4 in RPE internal
membranes is in further support that accumulation
of autoﬂuorescent precursors may contribute to
both RPE- and outer photoreceptor segment dys-
function, leading to lipofuscin buildup.13,29 These
equilibriums possibly contribute to the shorter life-
times identiﬁed in the newly formed deposits in
STGD.20,22
In addition, other components such as melanin have
been suggested to be involved in the disease process.
Melanin is concentrated at the fovea in the RPE cells
and has been shown to decrease in normal aging.30 It
has been speculated that lipofuscin buildup in the RPE
cells is partly inﬂuenced by melanin.31
Fig. 3. Disease progression
within 6- and 32-month follow-
up (Patient STGD 9). Color
fundus (CF), FAF intensity, and
ﬂuorescence lifetime (FLIO,
LSC) images. Correlating OCT
scan of the indicated lines in the
FLIO images are shown below.
From baseline (left) to 6-month
follow-up (middle), to 32-month
follow-up (right), clear disease
progression is visible with tran-
sition of ﬂecks with short ﬂuo-
rescence lifetimes (red arrows
and corresponding black arrows
in FLIO) to ﬂecks with long
ﬂuorescence lifetimes (blue ar-
rows and corresponding black
arrows in FLIO) and appearance
of new hyperﬂuorescent ﬂecks.
*Indicates a ﬂeck with short
ﬂuorescence lifetime initially
not visible on FAF intensity
image at baseline, but detectable
on follow-up.
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As described in previous clinical studies, our
longitudinal FLIO measurements revealed that ﬂeck
formation begins centrally in the foveal area,
radiating outward as the disease progresses. In
addition, new lesions often develop in close prox-
imity to existing ﬂecks, probably due to toxic effects
of visual by-products on neighboring RPE cells and
photoreceptors.5
Despite previous studies, the exact location of ﬂecks
remains controversial. On colocalization of the ﬂecks
to the OCT bands, we identiﬁed a variety of shapes
and sizes of hyperﬂuorescent accumulations at the EZ
and/or external limiting membrane bands. However,
an anatomical link to the RPE layer was present,
suggesting that the lipofuscin deposits begins in the
RPE and then migrates toward the inner retinal layers.
As previously observed by Voigt et al,32 we hypothe-
size that the different forms of deposits observed in the
OCT bands represent different phases in the natural
history of ﬂeck progression. Although ﬂecks with var-
ied ﬂuorescence intensities were identiﬁed, we could
not detect a correlation to the interruption of EZ, exter-
nal limiting membrane, or outer nuclear layer bands.
On analysis of OCT sections, we observed that at
earlier stages of the disease, the hyperreﬂective mate-
rial was restricted to the area underneath the EZ,
whereas at later stages, lesions with longer lifetimes
tended to progress through the EZ into the outer retinal
layers.
A useful tool to investigate the characteristics and
progression of STGD is the 2D histogram analysis.
Information from endogenous ﬂuorophores can be
obtained by analyzing the individual short (T1) and
long (T2) decay components, which contribute to the
mean ﬂuorescence lifetime (Tm). As different ﬂuoro-
phores have distinct lifetime patterns, speciﬁc retinal
structures can be demarcated. This technique can be
used to identify short and long decay times in separate
clusters (Figure 5). Furthermore, analysis of long life-
time ﬂecks revealed that the borders display shorter
lifetimes than the center of a ﬂeck. These ﬁndings
are in keeping with the observation that short lifetime
ﬂecks progress to long lifetime ﬂecks from the center
outward. This suggests that the short ﬂuorescence life-
time ﬂecks are composed of slightly different ﬂuoro-
phore components than the long lifetime ﬂecks.
Sparrow et al33 identiﬁed an increased signal within
ﬂecks using short-wavelength FAF. They purposed
that early on in STGD, the RPE cell layer is altered,
and that the enhanced short-wavelength FAF signal
could arise secondary to RPE atrophy and augmented
lipofuscin accumulation. These ﬁndings may provide
some insight into the possible sequence of retinal
changes in STGD.
There are some limitations to this study. Primarily,
in one patient, the diagnosis of STGD was largely
based on clinical assessment, and in one patient, an
autosomal dominant inheritance trait was identiﬁed.
Patients displayed a variable degree of disease severity
from early or childhood-onset to late-onset of STGD.
We also acknowledge that the data provided in this
report showed a cohort of patients with an atypical
Fig. 4. Analysis of disease
progression of hyperﬂuorescent
ﬂecks within 44-month follow-
up: autoﬂuorescence intensity
image (FAF), and ﬂuorescence
lifetime (FLIO, LSC) with
selected hyperﬂuorescent ﬂecks
(blue arrows) and corresponding
OCT scans. Follow-up exami-
nations show a clear progression
of ﬂecks in different imaging
modalities, with changes in
intensities and hyperreﬂective
material deposits on OCT.
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presentation including an older age of onset of
symptoms and a higher progression rate of atrophic
lesions in comparison to the ProgStar cohort.34,35 Fur-
thermore, a larger sample size would have provided
more information. However, despite the small cohort,
the ﬁndings of conversion of retinal ﬂecks were con-
sistent between patients. Concerns about the long-term
effects and the relationship between short-wavelength
light and the generation of toxic products have been
raised, especially patients with STGD. However, the
light exposure of the FLIO device is well below the
limits recommended by the ANSI standard for safe use
of lasers.36
Conclusions
In STGD, retinal ﬂuorescence lifetimes can be used
to analyze hyperﬂuorescent ﬂecks. Fluorescence life-
time imaging ophthalmoscopy has the potential of
becoming a monitoring tool in retinal conditions by
illustrating metabolic malfunctions and providing
further information about the composition of endoge-
nous retinal ﬂuorophores. This study establishes that
fundus autoﬂuorescence lifetimes demonstrate
explicit, reproducible patterns in STGD, and conﬁrms
the diagnostic value of FLIO as a non-invasive
imaging modality.
Using FLIO, we present a method of monitoring and
quantifying disease progression in patients with
STGD. Patterns of disease progression, when quanti-
ﬁed, could be useful in the development of new
outcome measurements for clinical trials testing novel
therapies for STGD. Since these changing autoﬂuor-
escence lifetime patterns may reﬂect intracellular
events in RPE cells, they may be helpful in gauging
the biological effect of potential therapies and in
interpreting treatment effects.
Key words: ﬂuorescence lifetimes, fundus auto-
ﬂuorescence, ophthalmic imaging, Stargardt disease,
macular dystrophy.
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Fig. 5. A 2D analysis of short and long ﬂuorescence lifetime compo-
nents T1 and T2. Distribution histograms (bottom) are shown of
a patient with STGD with short and long ﬂuorescence lifetime ﬂecks.
Speciﬁc areas are highlighted according to the lifetime distribution
clouds: surrounding retina, short ﬂuorescence lifetime ﬂecks, long
lifetime ﬂecks, and optic nerve head. Corresponding ﬂuorescence life-
time image (FLIO, LSC), FAF intensity, and OCT scan.
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